CARA (caratherapeutics.com) Earnings growth forecast for next year

Cara Therapeutics, Inc. (CARA) leads in pruritus therapy thanks to the drug Korsuva and the potential of new oral formulations. The valuation of forward net income growth rates visualizes these expectations, where 25.00 determines this parameter level. Stable revenue is ensured by the integration of systems for dialysis patients into medical centers, while the environmental profile is based on laboratory safety and digital administration.
Analytical breakdowns and data insights for company Cara Therapeutics Inc. (CARA)

Due to the absence of capital expenditures and the receipt of royalties from the sales of renal pruritus drugs, Cara Therapeutics, Inc. (CARA) demonstrates high free cash flow efficiency. Next year's earnings per share growth model reflects the expert consensus forecast for EPS dynamics, allowing investors to determine the extent to which the current market value aligns with the expected scaling of the business's net profit.